A Brazilian institute said on Wednesday the COVID-19 vaccine developed by China’s Sinovac Biotech has an efficacy rate of more than 50 percent based on trial data, but again withheld the full results, Reuters reported.
A vaccine with an efficacy rate over the 50 percent threshold is what the international medical community deems necessary to protect people.
The results for the late-stage trials of Sinovac’s vaccine, called CoronaVac, has now been delayed three times at the company’s request, which has added to concerns that Chinese vaccine makers have lacked transparency, Reuters said.
Officials from Sao Paulo state’s Butantan Institute, which is organised the late-stage trials, said Sinovac asked them to delay releasing precise vaccine efficacy data for up to 15 days from Wednesday while the company consolidates data from global trials, according to Reuters.
Turkey is in line to receive 50 million doses of CoronaVac and is expected to begin administering it in late December. However, Bloomberg reported on last week that the last phase of human trials for the vaccine is not expected to conclude until early next year.
On Wednesday, the Turkish Health Ministry reported 259 coronavirus-related deaths in the last 24 hours. Turkey’s death toll has continued to hit near-daily record highs since mid-November.
Turkey also recorded 19,650 new coronavirus cases in the last 24 hours, raising the total cases since March to 2,082,610, according to the ministry’s data.